Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide–drug conjugate via activating somatostatin receptor type II

References

• Mologni L, Cleris L, Magistroni V, et al. Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 2009;124:1990–6
   PubMed Web of Science ®Google Scholar
• Wedel S, Hudak L, Seibel JM, et al. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 2011;88:418–24
   PubMed Web of Science ®Google Scholar
• Sami S, Hoti N, Xu HM, et al. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 2008;144:357–62
   PubMed Web of Science ®Google Scholar
• Shabbeer S, Kortenhorst MS, Kachhap S, et al. Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 2007;67:1099–110
   PubMed Web of Science ®Google Scholar
• Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003;37:17–24
   PubMedGoogle Scholar
• Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734–41
   PubMed Web of Science ®Google Scholar
• Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:479364
   PubMed Web of Science ®Google Scholar
• Kim B, Rincon Castro LM, Jawed S, Niles LP. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur J Pharmacol 2008;589:45–8
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Sarkar FH. Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci 2010;11:398–408
   PubMed Web of Science ®Google Scholar
• Kostrouchova M, Kostrouch Z, Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol 2007;53:37–49
   PubMed Web of Science ®Google Scholar
• Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000;37:103–10
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5 doi: 10.1186/1756-8722-3-5
   PubMed Web of Science ®Google Scholar
• David G, Alland L, Hong SH, et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998;16:2549–56
   PubMed Web of Science ®Google Scholar
• Juengel E, Engler J, Mickuckyte A, et al. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 2010;105:549–57
   PubMed Web of Science ®Google Scholar
• Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007;12:942–51
   PubMed Web of Science ®Google Scholar
• Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 2008;144:956–61; discussion 61–2
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine 2012;41:40–52
   PubMed Web of Science ®Google Scholar
• Oberg K. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 2012;24:433–40
   PubMed Web of Science ®Google Scholar
• Yim KL. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Endocrine 2011;40:181–6
   PubMed Web of Science ®Google Scholar
• Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 1998;3:339–45
   PubMedGoogle Scholar
• Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008;20:1–12
   PubMed Web of Science ®Google Scholar
• Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858–68
   PubMed Web of Science ®Google Scholar
• Schnirer II, Yao JC, Ajani JA. Carcinoid – a comprehensive review. Acta Oncol 2003;42:672–92
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34:206–22
   PubMed Web of Science ®Google Scholar
• Iwahashi S, Utsunomiya T, Imura S, et al. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II. Anticancer Res 2014;34:5187–91
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2015;121:556–61
   PubMed Web of Science ®Google Scholar
• Avallone A, Piccirillo MC, Delrio P, et al. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid – short RadioTherapy – rectum 3rd trial). BMC Cancer 2014;14:875
   PubMed Web of Science ®Google Scholar
• Abaza MS, Bahman AM, Al-Attiyah RJ. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms. Int J Mol Med 2014;34:513–32
   PubMed Web of Science ®Google Scholar
• Franko-Tobin LG, Mackey LV, Huang W, et al. Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist 2012;17:220–32
   PubMed Web of Science ®Google Scholar
• Sun LC, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 2011;8:2–10
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Halmos G, et al. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005;104:1312–21
   PubMed Web of Science ®Google Scholar
• Sun L, Luo J, Mackey LV, et al. Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target 2011;19:719–30
   PubMed Web of Science ®Google Scholar
• Kaemmerer D, Specht E, Sanger J, et al. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic and therapeutic markers. J Clin Endocrinol Metab 2015;100:831–40
   PubMed Web of Science ®Google Scholar
• Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer 2015;22:1–9
   PubMed Web of Science ®Google Scholar
• Arora S, Soundararajan R, Joshi P, et al. Somatostatin receptor expressing bilateral ovarian metastases detected by 68Ga DOTANOC PET/CT. Clin Nucl Med 2015;40:496–8
   PubMed Web of Science ®Google Scholar
• Sun LC, Mackey LV, Luo J, et al. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol 2008;2:491–9
   PubMedGoogle Scholar
• Chadwick N, Zeef L, Portillo V, et al. Identification of novel Notch target genes in T cell leukaemia. Mol Cancer 2009;8:35 doi: 10.1186/1476-4598-8-35.
   PubMed Web of Science ®Google Scholar
• Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol 2009;16:481–6
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Haymart MR, Chen H. Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells. Transl Oncogenomics 2007;2:43–7
   PubMedGoogle Scholar
• Brodie SA, Brandes JC. Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticancer Ther 2014;14:1097–100
   PubMed Web of Science ®Google Scholar
• Mohammed TA, Holen KD, Jaskula-Sztul R, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011;16:835–43
   PubMed Web of Science ®Google Scholar
• Nguyen BC, Lefort K, Mandinova A, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev 2006;20:1028–42
   PubMed Web of Science ®Google Scholar
• Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079–86
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G636–42
   Google Scholar
• Xu Z, Choudhary S, Voznesensky O, et al. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res 2006;66:6657–64
   PubMed Web of Science ®Google Scholar